Cholbam
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bile Acid Synthesis Disorders
Conditions
Bile Acid Synthesis Disorders
Trial Timeline
Jul 10, 2017 → Jul 1, 2039
NCT ID
NCT03115086About Cholbam
Cholbam is a pre-clinical stage product being developed by Mirum Pharmaceuticals for Bile Acid Synthesis Disorders. The current trial status is active. This product is registered under clinical trial identifier NCT03115086. Target conditions include Bile Acid Synthesis Disorders.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03115086 | Pre-clinical | Active |
Competing Products
13 competing products in Bile Acid Synthesis Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 77 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 52 |
| Gemcitabine + Cisplatin + Durvalumab | AstraZeneca | Phase 2 | 52 |
| IL-10 | Merck | Phase 2 | 52 |
| aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil | Merck | Phase 2 | 52 |
| LJN452 + Placebo to LJN452 | Novartis | Phase 2 | 52 |
| Regorafenib | Bayer | Phase 2 | 49 |
| Gemcitabine + Cisplatin + Sorafenib | Bayer | Phase 2 | 49 |
| A3384 | Ipsen | Phase 2 | 49 |
| Cabozantinib | Exelixis | Phase 2 | 49 |
| Cholic acid | Mirum Pharmaceuticals | Phase 3 | 74 |
| Cholic Acid | Mirum Pharmaceuticals | Phase 3 | 74 |
| GM-CT-01 + 5-Fluorouracil | Galectin Therapeutics | Phase 2 | 44 |